Together, the exclusion of prM, maintenance of native E protein structure, and an immunoglobulin response less prone to pathological FcγR engagement all contribute to the markedly lower risk of ADE with dengue VLP vaccines. This evidence concerns the gene FCGR2A and dengue disease.